Notizia - Recent Pharma, Healthcare and Biotech Happenings

Pharma News and Updates for BMS, Biogen, Merck, Moderna, and Takeda

Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor

NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisation to Exkivity as monotherapy for non-small-cell lung cancer patients. At the same time, NHS England, cost-effectiveness watchdog NICE and Takeda have agreed on an early access deal for the drug that includes a discount on its monthly cost of around $25,000. According to Sajid Javid, Secretary of Health and Social Care, Exkivity will be available to ...

Explore More...

Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials

In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up

AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

Vir’s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines

In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure

Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Bristol Myers’ Opdivo combo Opdualag for Melanoma; Biogen’s Aduhelm; Marinus’ Ztalmy for CDKL-5 Deficiency Disorder; Merck’s Keytruda + Lynparza; Vitaris’s Breyna; Moderna’s Second COVID-19 Booster Shot; Takeda’s Exkivity; BMS’s First LAG-3 Checkpoint Inhibitor

Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials

In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up

AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes

COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market

Vir’s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines

In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure

Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

More Views & Analysis

Niacin fights Glioblastoma, iTeos nets $125M, Pandion reels in $80M, Brii, Chinese partner, FDA to speed up COVID-19 therapies

J&J’s COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott’s POC test; Cobra Bio raises $ 3.3 M

FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million

Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid

Sage seeks to save depression drug; Regeneron aims clinical trial; J&J sets sights for COVID-19 trial

Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib

JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment

Subscribe to our Updates

Daily

Weekly

Monthly